Oculis Holding AG

NASDAQ:OCS

Biotechnology

Healthcare
$7.39 -2.43%

-$0.28 today

Market cap
$456.20M
Beta
0.13
P/E (TTM)
-5.5
EPS (TTM)
-$1.61
52W Low $10.52High $34.48

Volume 0.31M

Average 0.65M

OCS Income Tax Expense

Income taxes recognized for the period, including current and deferred tax.

Oculis Holding AGNASDAQ: OCS

Income Tax Expense · Q1 FY2026 · quarter ended Mar 2026

Income tax expense turns negative

Q1 FY2026 income tax expense was -CHF 100.19K, compared with CHF 7K a year earlier. Trailing-twelve-month income tax expense was -CHF 291.8K. Over 3 fiscal years it compounded at +47.8% a year.

Context

  • Income tax expense increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly income tax expense holds near -CHF 100.19K or moves back toward the trailing-twelve-month quarterly average of -CHF 72.95K.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-CHF 100.19K+44.5% QoQ
Last fiscal yearDec 2025
CHF 177.64K+211.0% YoY
LTMMar 2026
-CHF 291.8K-59.5% YoY
Income Tax Expense past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-1531.2%——
1 year+211.0%——
3-year CAGR+47.8%——
5-year CAGR——
10-year CAGR——

Income Tax Expense history

CHF · from the income statement

Latest · FY2025
177.64K CHF
Year-over-year change
+211.0%
4-year CAGR
+60.2%

Income Tax Expense vs competitors

How OCS compares with its peers on the latest reported figures

  • Peers report in different currencies, so income tax expense is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -59.5% is the 2nd highest of 5, against a peer median of -7404.2%.
  • Income tax expense amounts to 57.9% of revenue for OCS, versus a peer median of 1.0%.
OCS Competitors
Income Tax Expense for OCS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
HROWHarrow Health, Inc.LTM Mar 2026$3.8M USD+2257.8%+257.1%1.4%
OCULOcular Therapeutix, Inc.LTM Mar 2026$0 USD——0.0%
EYPTEyePoint Pharmaceuticals, Inc.LTM Mar 2026-$43K USD-147.8%—0.6%
OCSOculis Holding AGLTM Mar 2026-CHF 291.8K CHF-59.5%+47.8%57.9%
OTLKOutlook Therapeutics, Inc.LTM Mar 2026-$1.55M USD-55622.5%—466.7%
OKYOOKYO Pharma LimitedFY2025-$3.26M USD-14660.7%——
Peer median (excluding OCS) —-7404.2%+257.1%1.0%

Competitors are the stored peer set for OCS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

CHF
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue000686K0
Cost of Revenue00052.08M0
Gross Profit000(51.4M)0
Gross Margin———-7492.3%—
Research & Development9.57M22.22M29.25M52.08M54.52M
Selling, General & Admin4.1M6.74M14.72M21.81M24.63M
Operating Expenses13.23M32.38M80.71M21.81M79.15M
Depreciation & Amortization235K299K287K406K521.45K
EBITDA(13.17M)(31.9M)(87.09M)(85.53M)(93.37M)
EBITDA Margin———-12468.1%—
Operating Income(13.23M)(32.38M)(80.71M)(73.2M)(79.15M)
Operating Margin———-10671.1%—
Interest Income21K126K1.59M2.17M1.69M
Interest Expense5.12M6.44M1.46M639K795.55K
Other Income / Expenses(5.29M)(6.27M)(7.98M)(12.73M)(15.54M)
Income Before Tax(18.52M)(38.64M)(88.7M)(85.94M)(94.69M)
Pre-Tax Margin———-12527.3%—
Income Tax Expense27K55K107K(160K)177.64K
Net Income(18.55M)(38.7M)(88.8M)(85.78M)(94.51M)
Net Margin———-12503.9%—
EPS (Basic)(0.57)(1.18)(2.97)(2.12)(1.81)
EPS (Diluted)(0.57)(1.18)(2.97)(2.12)(1.81)
Weighted Avg Shares32.73M32.73M29.9M40.41M52.36M
Weighted Avg Shares (Diluted)32.73M32.73M29.9M40.41M52.36M

Oculis Holding AG

NASDAQ:OCS

Intrinsic Alpha fair value

Locked

Current Price

$7.39

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.